Mucovac2
A Phase I clinical trial to assess the safety and immunogenicity of three HIV CN54gp140 immunisations.
We are recruiting healthy women aged between 18 and 45 for a trial of a new vaccine which potentially could prevent HIV infection in future. The study schedule consists of 10 morning appointments over 6 months, all visits take place at St George’s Vaccine Institute, on the 2nd floor of Ingelby House.
There is an urgent need to develop methods to prevent HIV infection, given the continuing world-wide epidemic and an estimated 14,000 new infections a day.
The aim of this particular study is to assess the safety of a new potential HIV vaccine. We’ll also assess how well the vaccine stimulates the body’s immune system by testing your blood in the laboratory. However, this study is not designed to test whether the vaccine actually provides real life protection against HIV. Even if you participate in this study and your immune system is stimulated by the vaccine, this does not mean that you will have been protected against HIV and it will still be possible for you to acquire HIV in the future.
Unlike some other vaccines, the potential vaccine we are testing does not contain any active (live) or denatured (killed) whole HIV or any other vector (carrier) viruses. Instead, it consists of a protein (a part known as gp140) that is found on the surface of HIV. Our potential vaccine is similar to some HIV vaccines that have been tested previously, including one used in the trial that showed a small benefit, but the way it will be given is different.
Who is organising and funding the research?
The research is funded by The Wellcome Trust under the Grand Challenges in Global Health Initiative and the UK HIV Vaccine Consortium.
The trial is sponsored by St. George's University of London and has been approved by the South East London 1 Research Ethics Committee.
For more information please see www.helpmakehistory.mrc.ac.uk.
Or you can contact us direct on 02087252316 or email vaccine@sgul.ac.uk.
